Interventional Radiology
Online ISSN : 2432-0935
2 巻, 3 号
選択された号の論文の12件中1~12を表示しています
Original Research
  • Yuko Tsuboi, Takuji Yamagami, Nobuaki Tsuboi
    2017 年 2 巻 3 号 p. 59-63
    発行日: 2017年
    公開日: 2017/11/08
    [早期公開] 公開日: 2017/08/01
    ジャーナル フリー

    PURPOSE: To evaluate the usefulness and safety of the "dual-needle pumping technique" for central venous access port (CV port) obstruction due to thrombus or fibrin sheath formation.

    PATIENTS AND METHODS: For 25 patients who had a CV port obstruction due to thrombus or fibrin sheath formation between 2001 and 2016, we performed the "dual-needle pumping technique." The operator inserted two coreless needles in the port and alternately pumped the plungers of two syringes filled with distilled water or urokinase (UK) solution.

    RESULTS: Overall, we achieved recanalization in 22 patients (88%). In 6 patients, success in recanalization was achieved by using distilled water only, while in 2 patients, failure occurred by using distilled water only before changing to the UK solution to achieve recanalization. Success in recanalization was attained in 14 patients by using the UK solution from the beginning. In 3 patients, the CV port system was withdrawn because the obstruction could not be removed. No complications occurred in relation to this procedure.

    CONCLUSION: For removing an obstruction in the CV port system, the "dual-needle pumping technique" is a reasonable option to avoid system replacement. Thus, this procedure is considered useful and safe.

  • Masakazu Hirakawa, Torahiko Yamanouchi, Satoru Tsuruta, Hidenari Hirat ...
    2017 年 2 巻 3 号 p. 64-73
    発行日: 2017年
    公開日: 2017/11/08
    [早期公開] 公開日: 2017/08/07
    ジャーナル フリー

    Purpose: This study aimed to retrospectively compare the local control and safety of microballoon-occluded transarterial chemoembolization (B-TACE) using miriplatin (MPT) and of conventional TACE (C-TACE) using epirubicin (EPIR) for hepatocellular carcinoma (HCC).

    Materials and Methods: Thirty-nine patients (24 men, 15 women; mean age, 73.4 years) were treated using B-TACE with MPT (MPT-B-TACE group). As a historical comparison, 23 patients (13 men, 10 women; mean age, 72.2 years) who were treated using C-TACE with EPIR (EPIR-C-TACE group) were investigated. The therapeutic effect within 2 weeks after treatment was compared between the groups based on the Response Evaluation Criteria in Cancer of the Liver (RECICL), and time to local recurrence was compared based on the Kaplan-Meier method and log-rank tests. The side effects were compared based on the Common Terminology Criteria for Adverse Events (ver. 4.0).

    Results: No significant differences were noted in patients' characteristics between the groups. The overall incidence of postembolization syndrome was significantly lower in the MPT-B-TACE group than in the EPIR-C-TACE group (p<0.05), but two cases in the MPT-B-TACE group developed grade 2 cholecystitis. Based on the RECICL, the objective response rate, including TE4 and TE3, within 2 weeks after treatment was significantly higher in the MPT-B-TACE group (89.7%) than in the EPIR-C-TACE group (78.3%). Overall, local recurrence was significantly less frequent in the MPT-B-TACE group than in the EPIR-C-TACE group (p=0.02).

    Conclusion: MPT-B-TACE was associated with a higher objective response rate and lower local recurrence rate than EPIR-C-TACE without a significant increase in adverse effects.

  • Yoshitaka Shida, Tomoyuki Noguchi, Takashi Okafuji, Kanako Murakami, T ...
    2017 年 2 巻 3 号 p. 74-78
    発行日: 2017年
    公開日: 2017/11/08
    [早期公開] 公開日: 2017/09/04
    ジャーナル フリー

    Purpose: To retrospectively determine the effectiveness of percutaneous vertebroplasty (PVP) for patients with ambulation difficulties due to acute osteoporotic vertebral fractures.

    Materials and Methods: We enrolled 62 patients who met the following criteria: almost normal ambulation before osteoporotic vertebral fracture, ambulation difficulties after onset, and a first-time PVP performed within 4 weeks. The patients were divided into Earlier (n = 46) or Later groups (n = 16) in which patients underwent PVP within 2 weeks or later, respectively. Mobility scores 7 days post-PVP in the Earlier group were compared with those 1 day before PVP in the Later group, that is, the conservatively waiting state. Earlier group values were also compared with those at 7 days post-PVP in the Later group to estimate the effectiveness of later PVP.

    Results: Mobility scores at 7 days post-PVP in Earlier group were significantly better than those 1 day before PVP in the Later group, suggesting that PVP provided mobility improvements sooner than the conservatively waiting state. Meanwhile, the lack of a difference in mobility scores at 7 days post-PVP between the Earlier and Later groups indicated that later PVP provided improvement comparable to earlier PVP.

    Conclusion: Earlier PVP contributes to earlier recovery from ambulation difficulties due to acute osteoporotic vertebral fractures than later PVP, while earlier and later PVP show equivalent efficacy in restoration of ambulation.

  • Hiroaki Ishii, Yasuaki Arai, Miyuki Sone, Shunsuke Sugawara, Shinichi ...
    2017 年 2 巻 3 号 p. 79-84
    発行日: 2017年
    公開日: 2017/11/08
    [早期公開] 公開日: 2017/10/05
    ジャーナル フリー

    Purpose: To evaluate the feasibility of drug-eluting bead (DEB)-transarterial chemoembolization (TACE) with 75 mg epirubicin for hepatocellular carcinoma (HCC) in Japanese patients with unresectable HCC prior to conducting a planned randomized controlled trial.

    Materials and Methods: This study was conducted as a prospective multi-center feasibility study. Eligible patients had unresectable Barcelona Clinic Liver Cancer stage A or B HCC that was unsuitable for curative treatments, and all patients received TACE with 75 mg epirubicin-loaded DEB. Tumor response, as the primary endpoint, was assessed after 4 weeks by computed tomography or magnetic resonance imaging, based on the modified Response Evaluation Criteria in Solid Tumors. Adverse events after treatment were evaluated as the secondary endpoint, based on the Common Terminology Criteria for Adverse Events version 4.0.

    Results: Between May and August 2014, 8 patients from two institutions were enrolled in this clinical study. There were no instances of complete response observed, partial response was obtained in 4 patients, and the overall response rate was 50%. No patients experienced grade 4 or higher adverse events. Grade 3 thrombocytopenia occurred in 1 patient. One patient experienced a grade 3 increase in aspartate aminotransferase, alanine aminotransferase, and bilirubin levels. All adverse events were well managed with conservative medical care. There were no procedure-related deaths.

    Conclusions: DEB-TACE with 75 mg epirubicin was found to be feasible in Japanese patients, and it was deemed appropriate to proceed to a randomized controlled trial comparing DEB-TACE and conventional TACE.

Case Report
Educational Paper from SIRAP
feedback
Top